MAPT and Alzheimer disease: Using this system, they demonstrated that Tau pathology was induced not by total Aβ levels but by high Aβ42/Aβ40 ratios, providing the first proof of this concept in human cells, suggesting that therapies able to diminish this Aβ42/Aβ40 ratio should be explored for AD [192].